Prognostic and predictive factors of breast carcinoma: Beyond hormonal receptors and HER2

Hanna, 1999, Evaluation of HER2/neu (erB-2) status in breast cancer: from bench to bedside, Mod Pathol, 12, 827 Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER“-positive breast cancer: a randomized controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2 Osborne, 1998, Steroid hormone receptors in breast cancer management Breast, Cancer Res Treat, 51, 227, 10.1023/A:1006132427948 Playne, 2008, Predictive markers in breast cancer – the present, Histopathology, 52, 82 Ellis, 2003, Invasive breast cancer, 13 Goldhirsch, 2007, Panel Members. Progress and promise: highlights of the international expert consensus on the primary of early breast cancer, Ann Oncol, 18, 1133, 10.1093/annonc/mdm271 Arnould, 2003, Agreement between chromogenic in situ hybridisation (CISH) and FISH in determination of HER2 status in breast cancer, Br J Cancer, 88, 1587, 10.1038/sj.bjc.6600943 Pauletti, 2000, Assessment of methods for tissue-based detection of the HER2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry, J Clin Oncol, 18, 3651, 10.1200/JCO.2000.18.21.3651 Harvey, 1999, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17, 1474, 10.1200/JCO.1999.17.5.1474 Owens, 2004, Her2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues, Clin Breast Cancer, 5, 63, 10.3816/CBC.2004.n.011 Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 Reis-Filho, 2008, Triple negative tumours: a critical review, Histopathology, 52, 108, 10.1111/j.1365-2559.2007.02889.x Diaz, 2007, Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice, Adv Anat Pathol, 14, 419, 10.1097/PAP.0b013e3181594733 Ranieri, 2006, Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic, Curr Med Chem, 13, 1845, 10.2174/092986706777585059 Pritchard, 2008, Her2 and topoisomerase II as predictors of response to chemotherapy, J Clin Oncol, 26, 736, 10.1200/JCO.2007.15.4716 Nagata, 2004, PTEN activation contributes to tumour inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell, 6, 117, 10.1016/j.ccr.2004.06.022 Natha, 2006, Mechanism of disease: understaining resistance to HER2-targeted therapy inhuman breast cancer, Nat Clin Pract Oncol, 3, 269, 10.1038/ncponc0509 Piccart-Gebhart M, The evolution of treatment strategies. Aiming at the target. St.Gallen 2007 Breast; 2007:16 (suppl). Liu, 2007, Downregulation of erb B3 abrogates erbb2-mediated tamoxifen resistance in breast cancer cells, Int J Cancer, 120, 1874, 10.1002/ijc.22423 Holbro, 2003, The erbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation, Proc Natl Acad Sci USA, 100, 8933, 10.1073/pnas.1537685100 Sundvall, 2008, Role of Erbb4 in breast cancer, J Mammary Gland Biol Neoplasia, 13, 259, 10.1007/s10911-008-9079-3 Singer, 2008, Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies, Biochim Biophys Acta